1-4 of 4
Michael Overman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer

Van Morris, Filip Janku, Helen Huang, Siqing Fu, Michael Overman, Sarina Piha-Paul, Vivek Subbiah, Bryan Kee, Apostolia Tsimbierdou, David Fogelman, Imad Shurieqi, Shanequa Manuel, Antonio Scamardo, Richard Lanman, Nicolas Sommer, David Hong, Scott Kopetz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A36.
DOI: https://doi.org/10.1158/1535-7163.TARG-15-A36
Published: 01 December 2015
View article
Journal Articles

Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer

Vivek Subbiah, David S. Hong, Behrang Amini, Sarina Piha-Paul, Joanna Grace Fernandez, Siquing Fu, Apostolia M. Tsimberidou, Aung Naing, Filip Janku, Daniel D. Karp, Michael Overman, Cathy Eng, Scott Kopetz, Funda Meric-Bernstam, Gerald S. Falchook
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C50.
DOI: https://doi.org/10.1158/1535-7163.TARG-15-C50
Published: 01 December 2015
View article
Journal Articles

Abstract B35: Acquired KRAS mutations after anti-EGFR therapy partially derive from low-frequency clones detectable in the primary tumor.

Maria Pia Morelli, Michael Overman, Arvind Dasari, Ali Kazmi, Edoardo Vilar-Sanchez, Cathy Eng, Bryan Kee, Laurel Deaton, Chris Garrett, Frank Diehl, Dipen Maru, Philipp Angenendt, Scott Kopetz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B35.
DOI: https://doi.org/10.1158/1535-7163.TARG-13-B35
Published: 01 November 2013
View article
Journal Articles

Abstract B121: Phase I study of MK‐0646, a humanized monoclonal antibody against IGF‐1R in combination with gemcitabine or gemcitabine + erlotinib (E) for advanced previously untreated pancreatic cancer

Milind Javle, Gauri Varadhachary, Priya Bhosale, Rachna Shroff, Lerma Ukegbu, Michael Overman, Robert Wolff, James Abbruzzese
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B121.
DOI: https://doi.org/10.1158/1535-7163.TARG-09-B121
Published: 10 December 2009
View article